Javascript must be enabled to continue!
Photosensitivity in HIV‐Infected Individuals
View through CrossRef
AbstractObjectiveTo characterize photosensitivity in HIV‐infected individuals using minimal erythema dosage (MED) UVA (ultraviolet A light) and UVB (ultraviolet B light) photoprovocation light testing.DesignProspective, controlled analytical studySettingUniversity of California, San Francisco, between March 1995 and January 1997.Patients13 HIV‐seropositive patients with clinical and pathological features consistent with photodermatitis, 13 HIV‐seropositive patients with biopsy‐proven eosinophilic foliculitis (EF), and 10 HIV‐seropositive patients with CD4 (T helper cell) count below 200 cells/uL and no history of photosensitivity or EF.InterventionEach patient underwent MED testing for UVB. All 13 patients with suspected photodermatitis underwent full photochallenge testing with UVA and UVB for up to 10 consecutive week days.ResultsMean MED to UVB in patients with clinical photosensitivity and EF was lower (p=0.004 and p=0.022 respectively) than that of patients without a clinical history of photodermatitis. There were no significant differences in mean CD4 count or Fitzpatrick skin type. Positive photochallenge tests (papular changes at site of provocative light testing) to UVB (9 of 13 patients) were much more common than reactions to UVA (3 of 13 patients) in the photodermatitis group. All patients with clinically active photodermatitis developed papular changes at the site of UVB photochallenge testing, but only 1 of 5 patients with photodermatitis in remission developed papular changes with UVB photochallenge testing. Seven of the 13 patients with photodermatitis had Native American ancestry. Photosensitive patients were commonly taking trimethoprim‐sulfamethoxazole (TMP‐SMX), but no more commonly than EF or control patients.ConclusionsPhotosensitivity in HIV‐infected individuals appears to be a manifestation of advanced disease. Most patients are sensitive to UVB. The most severely affected individuals are both UVB and UVA sensitive, and may show reactions to visible light. A significant Native American ancestry may be a risk factor for development of photodermatitis in patients with advanced HIV disease. Finally, patients with eosinophilic folliculitis may be subclinically photosensitive.
Title: Photosensitivity in HIV‐Infected Individuals
Description:
AbstractObjectiveTo characterize photosensitivity in HIV‐infected individuals using minimal erythema dosage (MED) UVA (ultraviolet A light) and UVB (ultraviolet B light) photoprovocation light testing.
DesignProspective, controlled analytical studySettingUniversity of California, San Francisco, between March 1995 and January 1997.
Patients13 HIV‐seropositive patients with clinical and pathological features consistent with photodermatitis, 13 HIV‐seropositive patients with biopsy‐proven eosinophilic foliculitis (EF), and 10 HIV‐seropositive patients with CD4 (T helper cell) count below 200 cells/uL and no history of photosensitivity or EF.
InterventionEach patient underwent MED testing for UVB.
All 13 patients with suspected photodermatitis underwent full photochallenge testing with UVA and UVB for up to 10 consecutive week days.
ResultsMean MED to UVB in patients with clinical photosensitivity and EF was lower (p=0.
004 and p=0.
022 respectively) than that of patients without a clinical history of photodermatitis.
There were no significant differences in mean CD4 count or Fitzpatrick skin type.
Positive photochallenge tests (papular changes at site of provocative light testing) to UVB (9 of 13 patients) were much more common than reactions to UVA (3 of 13 patients) in the photodermatitis group.
All patients with clinically active photodermatitis developed papular changes at the site of UVB photochallenge testing, but only 1 of 5 patients with photodermatitis in remission developed papular changes with UVB photochallenge testing.
Seven of the 13 patients with photodermatitis had Native American ancestry.
Photosensitive patients were commonly taking trimethoprim‐sulfamethoxazole (TMP‐SMX), but no more commonly than EF or control patients.
ConclusionsPhotosensitivity in HIV‐infected individuals appears to be a manifestation of advanced disease.
Most patients are sensitive to UVB.
The most severely affected individuals are both UVB and UVA sensitive, and may show reactions to visible light.
A significant Native American ancestry may be a risk factor for development of photodermatitis in patients with advanced HIV disease.
Finally, patients with eosinophilic folliculitis may be subclinically photosensitive.
Related Results
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Background: HIV rapid diagnosis in The Gambia is mainly done using Determine HIV-1/2 and First Response HIV 1.2.0 or SD Bioline HIV-1/2 3.0 for screening and sero-typing of HIV res...
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Background: The HIV pandemic has attracted unprecedented scale-up in resources to curb its escalation and manage those afflicted. Although evidence from developing countries sugges...
A novel high throughput microwell outgrowth assay for HIV infected cells
A novel high throughput microwell outgrowth assay for HIV infected cells
AbstractAlthough antiretroviral therapy (ART) is highly effective at suppressing HIV replication, a viral reservoir persists that can reseed infection if ART is interrupted. Curing...
A novel high-throughput microwell outgrowth assay for HIV-infected cells
A novel high-throughput microwell outgrowth assay for HIV-infected cells
ABSTRACT
Although antiretroviral therapy (ART) is effective at suppressing HIV replication, a viral reservoir persists that can reseed infection...
Seroprevalence and risk factors for Toxoplasmosis in HIV infected and non-infected individuals in Bahir Dar, Northwest Ethiopia
Seroprevalence and risk factors for Toxoplasmosis in HIV infected and non-infected individuals in Bahir Dar, Northwest Ethiopia
AbstractBackgroundToxoplasmosis, a zoonotic disease distributed worldwide, is an infection caused by the ubiquitous obligatory intracellular coccidian protozoan organism,Toxoplasma...
Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice
Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice
Abstract
Background
Since HIV+ treatment has become more effective, the average age of people living with HIV (PLWHIV) has increased, and consequently the incidence of developing c...
Stigma Kills
Stigma Kills
Stigma due to an HIV diagnosis is a well-known phenomenon and is a major barrier to accessing care.1Over the last forty years, HIV has been transformed from a fatal disease to a ma...

